Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adenosine receptors as drug targets — what are the challenges?
Jiang‐Fan Chen, Holger K. Eltzschig, Bertil B. Fredholm
Nature Reviews Drug Discovery (2013) Vol. 12, Iss. 4, pp. 265-286
Open Access | Times Cited: 820

Showing 1-25 of 820 citing articles:

Chromone: A Valid Scaffold in Medicinal Chemistry
Alexandra Gaspar, María João Matos, Jorge Garrido, et al.
Chemical Reviews (2014) Vol. 114, Iss. 9, pp. 4960-4992
Closed Access | Times Cited: 655
Pharmacology of Adenosine Receptors: The State of the Art
Pier Andrea Borea, Stefania Gessi, Stefania Merighi, et al.
Physiological Reviews (2018) Vol. 98, Iss. 3, pp. 1591-1625
Open Access | Times Cited: 620
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams, James Smothers, Roopa Srinivasan, et al.
Nature Reviews Drug Discovery (2015) Vol. 14, Iss. 9, pp. 603-622
Closed Access | Times Cited: 432
How does adenosine control neuronal dysfunction and neurodegeneration?
Rodrigo A. Cunha
Journal of Neurochemistry (2016) Vol. 139, Iss. 6, pp. 1019-1055
Open Access | Times Cited: 395
Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials
Ian D. Clark, Hans‐Peter Landolt
Sleep Medicine Reviews (2016) Vol. 31, pp. 70-78
Open Access | Times Cited: 384
Purinergic Signalling: Therapeutic Developments
Geoffrey Burnstock
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 346
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Akio Ohta
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 331
Transcriptional regulation of myeloid-derived suppressor cells
Thomas Condamine, Jérôme Mastio, Dmitry I. Gabrilovich
Journal of Leukocyte Biology (2015) Vol. 98, Iss. 6, pp. 913-922
Open Access | Times Cited: 322
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Paul A. Beavis, Upulie Divisekera, Christophe Paget, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 36, pp. 14711-14716
Open Access | Times Cited: 315
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Arabella Young, Deepak Mittal, John Stagg, et al.
Cancer Discovery (2014) Vol. 4, Iss. 8, pp. 879-888
Closed Access | Times Cited: 281
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Akio Ohta, Michail V. Sitkovsky
Frontiers in Immunology (2014) Vol. 5
Open Access | Times Cited: 272
Enzymes involved in metabolism of extracellular nucleotides and nucleosides: Functional implications and measurement of activities
Gennady G. Yegutkin
Critical Reviews in Biochemistry and Molecular Biology (2014) Vol. 49, Iss. 6, pp. 473-497
Closed Access | Times Cited: 272
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
Alisa Glukhova, David M. Thal, Thi Nguyen, et al.
Cell (2017) Vol. 168, Iss. 5, pp. 867-877.e13
Open Access | Times Cited: 270
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Detlev Boison, Gennady G. Yegutkin
Cancer Cell (2019) Vol. 36, Iss. 6, pp. 582-596
Open Access | Times Cited: 256
Immunosuppressive activities of adenosine in cancer
Bertrand Allard, Paul A. Beavis, Phillip K. Darcy, et al.
Current Opinion in Pharmacology (2016) Vol. 29, pp. 7-16
Closed Access | Times Cited: 250
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Carla Riera‐Domingo, Annette Audigé, Sara Granja, et al.
Physiological Reviews (2019) Vol. 100, Iss. 1, pp. 1-102
Open Access | Times Cited: 250
Medicinal chemistry of adenosine, P2Y and P2X receptors
Kenneth A. Jacobson, Christa E. Müller
Neuropharmacology (2015) Vol. 104, pp. 31-49
Open Access | Times Cited: 241
Effects of caffeine on the human circadian clock in vivo and in vitro
Tina M. Burke, Rachel R. Markwald, Andrew W. McHill, et al.
Science Translational Medicine (2015) Vol. 7, Iss. 305
Open Access | Times Cited: 236
ATP as a multi-target danger signal in the brain
Ricardo J. Rodrigues, Ângelo R. Tomé, Rodrigo A. Cunha
Frontiers in Neuroscience (2015) Vol. 9
Open Access | Times Cited: 224
CD150high Bone Marrow Tregs Maintain Hematopoietic Stem Cell Quiescence and Immune Privilege via Adenosine
Yuichi Hirata, Kazuhiro Furuhashi, Hiroshi Ishii, et al.
Cell stem cell (2018) Vol. 22, Iss. 3, pp. 445-453.e5
Open Access | Times Cited: 221
Purinergic signaling in the immune system
Francesco Di Virgilio, Marta Vuerich
Autonomic Neuroscience (2015) Vol. 191, pp. 117-123
Open Access | Times Cited: 211
Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
Michail V. Sitkovsky, Stephen Hatfield, Robert Abbott, et al.
Cancer Immunology Research (2014) Vol. 2, Iss. 7, pp. 598-605
Open Access | Times Cited: 196
The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine
Ludivine Baron, Aurélie Gombault, Manoussa Fanny, et al.
Cell Death and Disease (2015) Vol. 6, Iss. 2, pp. e1629-e1629
Open Access | Times Cited: 195
Regulation of the Cerebral Circulation by Arterial Carbon Dioxide
Ryan L. Hoiland, Joseph A. Fisher, Philip N. Ainslie
Comprehensive physiology (2019), pp. 1101-1154
Closed Access | Times Cited: 189
The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease
Jiang‐Fan Chen, Rodrigo A. Cunha
Purinergic Signalling (2020) Vol. 16, Iss. 2, pp. 167-174
Open Access | Times Cited: 185
Page 1 - Next Page

Scroll to top